B1MG - Beyond 1 Million Genomes
The EU-funded B1MG project will provide the support and coordination structure for the European 1+ Million Genomes initiative based on the commitment of 20 EU states and Norway to work ‘towards access to at least 1 million sequenced genomes in the EU by 2022’. These countries will engage a range of stakeholders to support the creation of a pan-European genome-based health data infrastructure, encompassing data quality and exchange standards, access protocols and legal guidance.
The BeYond-COVID project aims to make COVID-19 data accessible to scientists in laboratories but also to anyone who can use it, such as medical staff in hospitals or government officials.
Going beyond SARS-CoV-2 data, the project will provide a framework for making data from other infectious diseases open and accessible to everyone.
CINECA’s vision is a federated cloud enabled infrastructure making population scale genomic and biomolecular data accessible across international borders, accelerating research, and improving the health of individuals across continents. CINECA will leverage international investment in human cohort studies from Europe, Canada, and Africa to deliver a paradigm shift of federated research and clinical applications.
The CY-Biobank project revolves around the upgrading of the existing Biobank of the University of Cyprus, to a Center of Excellence in Biobanking and Biomedical Research, adapting European standards of operation in collaboration with the Advanced Partners. This medical research infrastructure will then serve the foundation for developing the Cyprus human genome project and other genomics/genetics projects for diseases with Mendelian inheritance as well as complex disorders of multifactorial character that impact modern societies.
The overall goal of EDIReX is to establish a cutting-edge European infrastructure offering Trans-national Access (TA) of PDX resources to academic and industrial cancer researchers, including the distribution of cryopreserved samples to third parties, the structured biobanking of user-developed models, and the performance of efficacy studies.
EOSC Future will unlock the potential of European research via a vision of Open Science for Society by (1) bringing all major stakeholders in the EOSC ecosystem together under one project umbrella to break the disciplinary and community silos and consolidate key EOSC project outputs, (2) developing scientific use cases in collaboration with the thematic communities showcasing the benefits and societal value of EOSC for doing excellent and interdisciplinary research, (3) engaging the wider EOSC community and increasing the visibility of EOSC through communications campaigns, marketing strategies, and physical and online engagement events, and (4) including the EOSC community in developing the EOSC Portal (including the long tail of science, public and private sectors, and international partners) via co-creation open calls.
The European Platform for Neurodegenerative Diseases (EPND) will tackle the above issues by developing a self-sustaining European-based platform to facilitate discovery and access of relevant bio-samples and data.
EuCanImage is a new large-scale international project (10 million Euros) funded by the European Commission to build a secure and federated imaging platform for next-generation artificial intelligence in oncology. The EuCanImage platform will be populated with a new data resource totalling over 25,000 single subjects, which will allow to investigate unmet clinical needs like never before, such as for the detection of small liver lesions and metastases of colorectal cancer, or for estimating molecular subtypes of breast tumours and pathological complete response.
HealthyCloud will deliver a Strategic Agenda including a Ready-to-implement Roadmap for the HRIC ecosystem. The Strategic Agenda will incorporate the consolidated feedback of a broad range of stakeholders.
The aim of INTERVENE is to develop and test next generation tools for disease prevention, diagnosis, and personalised treatment utilizing the first US-European pool of genomic and health data and integrating longitudinal and disease-relevant -omics data into genetic risk scores. Resulting in unprecedented potential for prediction, diagnosis, and personalised treatments for complex and rare diseases. Some of the largest biobanks in Europe and two in the USA will be securely linked and harmonized in a GDPR-compliant repository with data from more than 1.7 million genomes.
The ISIDORe consortium, made of the capacities of European ESFRI infrastructures and coordinated networks, proposes to assemble the largest and most diverse research and service providing instrument to study infectious diseases in Europe, from structural biology to clinical trials.
European and global research infrastructures (RIs) provide facilities and resources to support excellence and innovation, delivering socio-economic value by raising skills, advancing knowledge and technology and its exploitation, and driving new development and construction. RI-VIS will increase the visibility of European RIs to broader scientific communities, industry and strategic partners in third countries.
The mission of the EU-funded BIGPICTURE project is to establish the first European platform where quality-controlled whole slide imaging (WSI) data are stored. The consortium consists of Europe's largest pathology departments and will work towards an open-source framework for accessing, annotating and mining WSI data using AI algorithms. With access to millions of WSI data, BIGPICTURE envisions AI-based methods that can help clinicians interpret tissue features and perform diagnosis fast, in a high-throughput manner, avoiding human bias or error.
CETOCOEN Excellence will exploit research capacities built in Central Europe with support from the European Structural and Investment Fund and develop a cutting-edge research platform capable of addressing major scientific and societal challenges in contemporary Europe in the areas of environment and health.
ConcePTION will build an ecosystem for better monitoring and communicating of medication safety in pregnancy and lactation: validated and regulatory endorsed workflows for fast, optimised evidence generation.
The project DIAMONDS will address the challenge of bringing personalised medicine into routine use in EU healthcare systems for diagnosis and treatment of common infectious and inflammatory diseases, which account for a up to a third of all medical encounters in primary care and hospital.
The European Joint Programme on Rare Diseases brings over 130 institutions from 35 countries to create a comprehensive, sustainable ecosystem allowing a virtuous circle between research, care and medical innovation.
Its aims are to improve the integration, the efficacy, the production and the social impact of research on RD through the development, demonstration and promotion of Europe/world-wide sharing of research and clinical data, materials, processes, knowledge and know-how; and to implement and further develop an efficient model of financial support for all types of research on RD (fundamental, clinical, epidemiological, social, economic, health service) coupled with accelerated exploitation of research results for benefit of patients.
EOSC-Life brings together the 13 Biological and Medical ESFRI research infrastructures (BMS RIs) to create an open collaborative space for digital biology. The goal of the EOSC-Life project is to make sure that life-scientists can find, access and integrate life-science data for analysis and reuse in academic and industrial research.
This project is set up by all existing ERICs to strengthen coordination and networking reinforcing the informal ERIC network or its successor framework; support the organisation of specific meetings, targeted thematic workshops focussing on shared challenges; support ERICs in preparation, based on best practices; support common communication and outreach activities and strengthening external representation of ERICs as a stakeholder in consultations and other policy actions that could affect them.
EUCAN-Connect will enable large-scale integrated cohort data analysis for personalized and preventive healthcare across EU and Canada. EUCAN-Connect platform and collaborations will be coordinated through BBMRI-ERIC (EU) and Maelstrom Research (Canada) to sustain long-term benefits to science and citizens worldwide.
euCanSHare will develop the first centralised, secure and sustainable platform for enhanced cross-border data sharing and multi-cohort personalised medicine research in cardiology.
The role of BBMRI-ERIC in euCanSHare is to bring expertise in quality standards for data collection, presentation and evaluation, while ensuring its security and privacy, as well as the project communication and dissemination.
IC2PerMed project will provide key solutions for enabling the convergence under ICPerMed consortium of European and Chinese stakeholders towards a common approach of PM research, innovation, development and implementation involving policy makers and healthcare beneficiaries
The project RABBIT is to support EIT Health partners in simplifying access to biobanks and quality registries, and to help them leverage the assets available all over the Europe. The main goals of RABBIT 2 are:
A) Scale out of RABBIT in Europe, including increasing the number of project submissions using biobanks and registers in Regions from both large companies, Start-ups, Universities the public sector in Scandinavia and in other CLCs.
B) Scale up of RABBIT with further focus on needs, challenges and assets at Cities, public partners and health care payers.
Molecular in vitro diagnostics and biomedical research have allowed great progress in personalised medicine but further progress is limited by insufficient guidelines for pre-analytical workflow steps (sample collection, preservation, etc.) as well as by insufficient quality assurance of diagnostic practice. This allows using compromised patients’ samples with post collection changes in cellular and extra-cellular biomolecules’ profiles thus often making diagnostic test results unreliable or even impossible.
Thus, SPIDA4P aims to generate and implement a comprehensive portfolio of 22 pan-European pre-analytical CEN/TS and ISO/IS, addressing the important pre-analytical workflows applied to personalized medicine.